| Literature DB >> 26582246 |
Yongyan Song1, Yang Yang2, Jingxiao Zhang3, Yanmei Wang3,4, Wenfeng He3, Xiaoming Zhang5, Jie Zhu2, Zhan Lu6.
Abstract
BACKGROUND: Lipoprotein ratios have been shown to be associated with the occurrence of coronary heart disease (CHD), but little is known about their relationships with the severity of CHD.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26582246 PMCID: PMC4652387 DOI: 10.1186/s12944-015-0155-6
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Clinical characteristics of the CHD patients according to the tertile of the Gensini scores
| Variables | Group 1 | Group 2 | Group 3 |
|
|---|---|---|---|---|
| ≤33rd percentile ( | 33rd to 66th percentile ( | ≥66th percentile ( | ||
| Non-lipid variables | ||||
| Age, years | 62.06 ± 9.98 | 62.68 ± 10.61 | 64.95 ± 9.67 | 0.003 |
| Male gender, n (%) | 171 (64.5) | 172 (65.9) | 204 (76.7) | 0.004 |
| Weight, kg | 64.95 ± 9.29 | 63.39 ± 9.36 | 64.67 ± 9.63 | 0.225 |
| BMI, kg/m2 | 24.56 ± 2.84 | 24.15 ± 3.03 | 24.16 ± 3.04 | 0.399 |
| Smokers, n (%) | 95 (35.8) | 120 (46.0) | 133 (50.0) | 0.003 |
| Hypertension, n (%) | 119 (44.9) | 141 (54.0) | 138 (51.9) | 0.091 |
| Diabetes, n (%) | 35 (13.2) | 34 (13.0) | 51 (19.2) | 0.080 |
| Individual lipid variables | ||||
| TG, mmol/L | 1.53 ± 0.90 | 1.49 ± 1.09 | 1.66 ± 1.14 | 0.156 |
| TC, mmol/L | 4.16 ± 0.94 | 4.22 ± 1.01 | 4.23 ± 1.20 | 0.728 |
| HDL-C, mmol/L | 1.01 ± 0.29 | 1.02 ± 0.34 | 0.93 ± 0.29 | 0.001 |
| LDL-C, mmol/L | 2.37 ± 0.75 | 2.44 ± 0.81 | 2.49 ± 0.94 | 0.263 |
| ApoAI, g/L | 1.03 ± 0.19 | 1.02 ± 0.21 | 0.95 ± 0.21 | <0.001 |
| ApoB100, g/L | 0.76 ± 0.24 | 0.77 ± 0.25 | 0.80 ± 0.28 | 0.204 |
| Lipoprotein ratios | ||||
| TG/HDL-C | 1.83 ± 2.06 | 2.09 ± 4.41 | 2.16 ± 2.53 | 0.466 |
| TC/HDL-C | 4.51 ± 1.92 | 4.73 ± 3.58 | 5.03 ± 3.18 | 0.079 |
| LDL-C/HDL-C | 2.57 ± 1.11 | 2.70 ± 1.75 | 2.96 ± 2.01 | 0.024 |
| ApoB/apoAI | 0.76 ± 0.27 | 0.78 ± 0.29 | 0.88 ± 0.43 | <0.001 |
The differences across the tertile of the Gensini scores were calculated by Chi-square test for categorical variables, and one-way ANOVA analysis for continuous variables
BMI body mass index, TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, apoAI apolipoprotein AI, apoB100 apolipoprotein B100
Clinical characteristics of the CHD patients with different number of stenotic vessels
| Variables | Single-branch stenosis ( | Double-branch stenosis ( | Multi-branch stenosis ( |
|
|---|---|---|---|---|
| Non-lipid variables | ||||
| Age, years | 61.93 ± 10.25 | 63.04 ± 9.56 | 65.12 ± 10.25 | 0.001 |
| Male gender, n (%) | 197 (60.2) | 158 (74.5) | 193 (76.3) | <0.001 |
| Weight, kg | 64.26 ± 9.62 | 64.32 ± 8.71 | 64.43 ± 9.81 | 0.985 |
| BMI, kg/m2 | 24.43 ± 2.80 | 24.40 ± 3.15 | 24.31 ± 3.13 | 0.923 |
| Smokers, n (%) | 119 (36.4) | 103 (48.6) | 123 (48.6) | 0.003 |
| Hypertension, n (%) | 155 (47.4) | 97 (45.8) | 142 (56.1) | 0.045 |
| Diabetes, n (%) | 37 (11.3) | 32 (15.1) | 51 (20.2) | 0.013 |
| Individual lipid variables | ||||
| TG, mmol/L | 1.44 ± 0.80 | 1.63 ± 1.08 | 1.67 ± 1.30 | 0.049 |
| TC, mmol/L | 4.07 ± 0.87 | 4.32 ± 1.10 | 4.30 ± 1.22 | 0.028 |
| HDL-C, mmol/L | 1.03 ± 0.308 | 0.99 ± 0.33 | 0.94 ± 0.30 | 0.003 |
| LDL-C, mmol/L | 2.31 ± 0.73 | 2.50 ± 0.83 | 2.56 ± 0.97 | 0.004 |
| ApoAI, g/L | 1.03 ± 0.20 | 1.00 ± 0.20 | 0.96 ± 0.22 | 0.001 |
| ApoB100, g/L | 0.74 ± 0.24 | 0.79 ± 0.25 | 0.80 ± 0.29 | 0.009 |
| Lipoprotein ratios | ||||
| TG/HDL-C | 1.64 ± 1.36 | 2.20 ± 2.70 | 2.43 ± 5.05 | 0.003 |
| TC/HDL-C | 4.26 ± 1.50 | 5.10 ± 4.01 | 5.12 ± 3.33 | <0.001 |
| LDL-C/HDL-C | 2.44 ± 1.03 | 2.87 ± 1.83 | 3.05 ± 3.05 | <0.001 |
| ApoB/apoAI | 0.74 ± 0.26 | 0.81 ± 0.28 | 0.88 ± 0.45 | <0.001 |
The differences across the groups with different number of stenotic vessels were calculated by Chi-square test for categorical variables, and one-way ANOVA analysis for continuous variables
BMI body mass index, TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, apoAI apolipoprotein AI, apoB100 apolipoprotein B100
Results of the univariate ordinal logistic regression of the lipoprotein ratios and the tertile of the Gensini scores or the number of stenotic vessels
| Variables | The tertile of the Gensini scores | The number of stenotic vessels | ||||
|---|---|---|---|---|---|---|
| OR | 95 % CI |
| OR | 95 % CI |
| |
| TG/HDL-C | 1.02 | 0.98–1.07 | 0.341 | 1.05 | 1.01–1.09 | 0.021 |
| TC/HDL-C | 1.05 | 1.00–1.10 | 0.034 | 1.09 | 1.04–1.14 | <0.001 |
| LDL-C/HDL-C | 1.12 | 1.02–1.23 | 0.017 | 1.20 | 1.10–1.31 | <0.001 |
| ApoB100/apoAI | 2.30 | 1.51–3.51 | <0.001 | 3.09 | 2.07–4.61 | <0.001 |
OR odds ratio, 95 % CI 95 % confidence interval, TG/HDL-C triglyceride/high-density lipoprotein cholesterol, TC/HDL-C total cholesterol/high-density lipoprotein cholesterol, LDL-C/HDL-C low-density lipoprotein cholesterol/high-density lipoprotein cholesterol, apoB100/apoAI apolipoprotein AI/apolipoprotein B100
Results of multivariate ordinal logistic regression of the lipoprotein ratios and the tertile of the Gensini scores or the number of stenotic vessels
| Variables | The tertile of the Gensini scores | The number of stenotic vessels | ||||
|---|---|---|---|---|---|---|
| OR | 95 % CI |
| OR | 95 % CI |
| |
| TG/HDL-C | ||||||
| Model 1 | 1.02 | 0.98–1.08 | 0.339 | 1.05 | 1.00–1.10 | 0.033 |
| Model 2 | 0.98 | 0.91–1.05 | 0.576 | 1.00 | 0.93–1.07 | 0.983 |
| Model 3 a | 0.98 | 0.91–1.05 | 0.536 | 1.04 | 0.90–1.21 | 0.600 |
| LDL-C/HDL-C | ||||||
| Model 1 | 1.16 | 1.02–1.31 | 0.019 | 1.39 | 1.22–1.58 | <0.001 |
| Model 2 | 0.99 | 0.827–1.19 | 0.909 | 1.01 | 0.83–1.22 | 0.960 |
| Model 3 b | 1.13 | 0.77–1.66 | 0.533 | 0.87 | 0.57–1.31 | 0.499 |
| TC/HDL-C | ||||||
| Model 1 | 1.07 | 1.01–1.14 | 0.030 | 1.13 | 1.06–1.21 | <0.001 |
| Model 2 | 0.97 | 0.89–1.72 | 0.485 | 0.99 | 0.91–1.08 | 0.888 |
| Model 3 b | 0.87 | 0.65–1.16 | 0.334 | 0.81 | 0.59–1.10 | 0.176 |
| ApoB100/apoAI | ||||||
| Model 1 | 2.73 | 1.60–4.66 | <0.001 | 4.79 | 2.80–8.20 | <0.001 |
| Model 2 | 3.18 | 1.30–7.76 | 0.011 | 2.55 | 1.04–6.28 | 0.041 |
| Model 3 c | 2.93 | 1.17–7.34 | 0.022 | 3.14 | 1.01–6.47 | 0.048 |
Model 1, adjusted for the non-lipid CHD risk factors including age, gender, weight, BMI, smoking, alcohol consumption, diabetes mellitus and hypertension; Model 2, adjusted for the variables in Model 1 plus the individual lipid variables including TG, HDL-C, LDL-C, apoB100 and apoAI; Model 3 a, adjusted for the variables in Model 2 plus the lipoprotein ratios including LDL-C/HDL-C and apoB100/apoAI; Model 3 b, adjusted for the variables in Model 2 plus the lipoprotein ratios including TG/HDL-C and apoB100/apoAI; Model 3 c, adjusted for the variables in Model 2 plus the lipoprotein ratios including TG/HDL-C and LDL-C/HDL-C
OR odds ratio, 95 % CI 95 % confidence interval, TG/HDL-C triglyceride/high-density lipoprotein cholesterol, TC/HDL-C total cholesterol/high-density lipoprotein cholesterol, LDL-C/HDL-C low-density lipoprotein cholesterol/high-density lipoprotein cholesterol, apoB100/apoAI apolipoprotein AI/apolipoprotein B100
Fig. 1Significant regression paths among dependent (the tertile of the Gensini scores) and independent variables. * P ≤ 0.05, ** P ≤ 0.01, standardized regression coefficients (β) or odds ratios (OR) represented as one-way arrows
Fig. 2Significant regression paths among dependent (the number of stenotic vessels) and independent variables. * P ≤ 0.05, ** P ≤ 0.01, standardized regression coefficients (β) or odds ratios (OR) represented as one-way arrows